BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29618565)

  • 1. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifapentine.
    Jarvis B; Lamb HM
    Drugs; 1998 Oct; 56(4):607-16; discussion 617. PubMed ID: 9806107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
    Ordonez AA; Wang H; Magombedze G; Ruiz-Bedoya CA; Srivastava S; Chen A; Tucker EW; Urbanowski ME; Pieterse L; Fabian Cardozo E; Lodge MA; Shah MR; Holt DP; Mathews WB; Dannals RF; Gobburu JVS; Peloquin CA; Rowe SP; Gumbo T; Ivaturi VD; Jain SK
    Nat Med; 2020 Apr; 26(4):529-534. PubMed ID: 32066976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.
    DeMarco VP; Ordonez AA; Klunk M; Prideaux B; Wang H; Zhuo Z; Tonge PJ; Dannals RF; Holt DP; Lee CK; Weinstein EA; Dartois V; Dooley KE; Jain SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5768-74. PubMed ID: 26169396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
    Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between sterilizing activity and drug distribution into tuberculosis lesions.
    Prideaux B; Via LE; Zimmerman MD; Eum S; Sarathy J; O'Brien P; Chen C; Kaya F; Weiner DM; Chen PY; Song T; Lee M; Shim TS; Cho JS; Kim W; Cho SN; Olivier KN; Barry CE; Dartois V
    Nat Med; 2015 Oct; 21(10):1223-7. PubMed ID: 26343800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
    Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
    Zurlinden TJ; Eppers GJ; Reisfeld B
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
    Savic RM; Weiner M; MacKenzie WR; Engle M; Whitworth WC; Johnson JL; Nsubuga P; Nahid P; Nguyen NV; Peloquin CA; Dooley KE; Dorman SE;
    Clin Pharmacol Ther; 2017 Aug; 102(2):321-331. PubMed ID: 28124478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Park SW; Tasneen R; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.